Migliaccio & Rathod LLP is investigating whether former Akoya Biosciences shareholders received misleading or incomplete information about Quanterix Corporation’s financial condition and expected profitability before the companies’ July 2025 merger.
On July 8, 2025, Quanterix completed its acquisition of Akoya Biosciences. Akoya shareholders received a combination of Quanterix shares and cash in exchange for their Akoya stock.
Before the merger, the companies promoted the transaction as creating a stronger life-sciences business with expanded commercial capabilities, significant cost savings, and a path toward becoming cash-flow breakeven in 2026.
However, the combined company’s financial performance subsequently fell short of those expectations.
These developments raise questions about whether Akoya shareholders received accurate information concerning the company’s revenue expectations, the value of its acquired assets, and the financial benefits anticipated from the merger.
Migliaccio & Rathod is investigating whether material financial risks were known or reasonably identifiable before the merger but were not adequately disclosed to Akoya shareholders.
Shareholders May Have Experienced:
- Receiving Quanterix shares in exchange for Akoya Biosciences shares;
- Relying on representations that the combined company would reach cash-flow breakeven in 2026;
- Experiencing investment losses following Quanterix’s August 2026 financial announcement;
- Holding Quanterix shares as the company recorded acquisition-related impairments; or
- Receiving merger consideration based on potentially misleading financial disclosures.
Potential Claims May Include:
- Material misrepresentations or omissions in merger-related disclosures;
- Failure to disclose material financial risks affecting the combined company;
- Misleading statements concerning anticipated profitability or acquired assets; or
- Violations of federal securities laws.
Signs You May Be Affected:
- You owned Akoya Biosciences shares before July 8, 2025;
- You received Quanterix shares as part of the merger;
- You received or reviewed merger-related disclosures;
- You held Quanterix shares following the acquisition;
- You experienced investment losses after Quanterix reduced its financial guidance; or
- You have brokerage statements documenting your Akoya holdings and Quanterix shares received.
If you have encountered these issues, we would like to hear from you. Please complete the contact form on this page, send us an email at [email protected], or give us a call.